



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit go.covermymeds.com/OptumRx to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Xeljanz® & Xeljanz XR® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting brand			Directions for Use:		
<input type="checkbox"/> Check if request is for continuation of therapy					
Clinical Information (required)					
Select the diagnosis:					
<input type="checkbox"/> Active psoriatic arthritis					
<input type="checkbox"/> Moderately to severely active rheumatoid arthritis					
<input type="checkbox"/> Moderately to severely active ulcerative colitis					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
Prescriber's Specialty:					
Select if Xeljanz/Xeljanz XR is prescribed by or in consultation with one of the following specialists:					
<input type="checkbox"/> Dermatologist					
<input type="checkbox"/> Gastroenterologist					
<input type="checkbox"/> Rheumatologist					
Clinical Information:					
Is this request for continuation of prior Xeljanz/Xeljanz XR therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select if the patient has had history of trial and failure, contraindication, or intolerance to the following, or attestation demonstrating a trial may be inappropriate:					
<input type="checkbox"/> Enbrel (etanercept)		<input type="checkbox"/> Cosentyx (secukinumab)		<input type="checkbox"/> Leflunomide	
<input type="checkbox"/> Cimzia (certolizumab)		<input type="checkbox"/> Humira (adalimumab)		<input type="checkbox"/> Simponi (golimumab)	
<input type="checkbox"/> Methotrexate (oral or injectable forms)		<input type="checkbox"/> Stelara (ustekinumab)			
Does the patient have a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure (refer to DSM-IV-TR 300.29 for specific phobia diagnostic criteria)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Will Xeljanz/Xeljanz XR be used in combination with a potent immunosuppressant (e.g., azathioprine, cyclosporine)? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For moderately to severely active ulcerative colitis, also answer the following:					
Select if the patient has had history of trial and failure, contraindication, or intolerance to the following conventional therapies:					
<input type="checkbox"/> 6-mercaptopurine (Purinethol)					
<input type="checkbox"/> Aminosalicylate [e.g., mesalamine (Asacol, Pentasa, Rowasa), olsalazine (Dipentum), sulfasalazine (Azulfidine, Sulfazine)]					
<input type="checkbox"/> Azathioprine (Imuran)					
<input type="checkbox"/> Corticosteroids (e.g., prednisone, methylprednisolone)					
Reauthorization:					
Is there documentation the patient has had a positive clinical response to Xeljanz/Xeljanz XR therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Will Xeljanz/Xeljanz XR be used in combination with a potent immunosuppressant (e.g., azathioprine, cyclosporine)? <input type="checkbox"/> Yes <input type="checkbox"/> No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Xeljanz-XeljanzXR_CMS_2019Feb-W



Xeljanz[®] & Xeljanz XR[®] Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Quantity Limit:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

- Titration or loading-dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- There is a medically necessary justification why the patient cannot use a higher commercially available strength to achieve the same dosage and remain within the same dosing frequency. **Please specify:** _____
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note:

This request may be denied unless all required information is received.

If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.

For urgent or expedited requests please call 1-800-711-4555.

This form may be used for non-urgent requests and faxed to 1-800-527-0531.